BREAKWATER: an Open-Label, Multicenter, Randomized, Phase 3 Study, with a Safety Leadin (SLI), of First-Line (1L) Encorafenib (E) Plus Cetuximab (C) 6 Chemotherapy (CT) Vs Standard-of-care (SOC) CT for BRAF V600E-mutant Metastatic Colorectal Cancer (Mcrc)